微小RNAs在心肌肥厚中作用和分子机制的研究进展

doi:10.16352/j.issn.1001-6325.2023.07.1167

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1167-1170.doi: 10.16352/j.issn.1001-6325.2023.07.1167

微小RNAs在心肌肥厚中作用和分子机制的研究进展

王帆, 邓勇志^*

山西医科大学附属心血管病医院山西省心血管病医院山西省心血管病临床医学研究中心心血管外科, 山西太原 030024

收稿日期:2022-03-03 修回日期:2022-11-13 发布日期:2023-07-05
通讯作者: ^*olympicschina@163.com

Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy

WANG Fan, DENG Yongzhi^*

Department of Cardiovascular Surgery, Shanxi Cardiovascular Hospital, the Affiliated Cardiovascular Hospital of Shanxi Medical University, the Clinical Medical Research Center of Shanxi Province, Taiyuan 030024, China

Received:2022-03-03 Revised:2022-11-13 Published:2023-07-05

摘要/Abstract

摘要： 微小RNAs(miRNAs)是一类非编码RNAs,与多种心血管疾病相关,包括高血压、心力衰竭和心肌梗死等。miRNAs的表达在心肌肥厚过程中通过调节心肌细胞自噬、炎性反应和能量代谢等过程调控心肌肥厚。

关键词: 心肌肥厚, 微小RNA, 作用靶点, 信号通路

Abstract: MicroRNAs(miRNAs) are a class of non-coding RNAs associated with a variety of cardiovascular diseases, including hypertension, heart failure and myocardial infarction. Expression of miRNAs changes during cardiac hypertrophy, which regulates cardiac hypertrophy by regulating cardiomyocyte autophagy, inflammatory response and energy metabolism. This article reviews the expression changes, potential targets and molecular mechanisms of miRNAs in cardiac hypertrophy.

Key words: cardiac hypertrophy, microRNA, target of action, signal pathway

中图分类号:

王帆, 邓勇志. 微小RNAs在心肌肥厚中作用和分子机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1167-1170.

WANG Fan, DENG Yongzhi. Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy[J]. Basic & Clinical Medicine, 2023, 43(7): 1167-1170.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.07.1167

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I7/1167

参考文献

[1] 《中国心血管健康与疾病报告2020》概述[J].中国心血管病研究,2021, 19: 582-590.
[2] Colpaert RMW, Calore M. MicroRNAs in cardiac diseases[J]. Cells, 2019, 18, 8: 737.doi:10.3390/cells8070737.
[3] Tu YF, Wan L, Bu LH, et al. MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention[J]. Cell Physiol Biochem, 2013, 31: 997-1008.
[4] Yang XY, Tao LH, Zhu J, et al. Long noncoding RNA FTX reduces hypertrophy of neonatal mouse cardiac myocytes and regulates the PTEN/PI3K/Akt signaling pathway by sponging microRNA-22[J]. Med Sci Monit, 2019, 25: 9609-9617.
[5] Kopechek JA, McTiernan CF, Chen X, et al. Ultrasound and microbubble-targeted delivery of a microRNA inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function[J]. Theranostics, 2019, 9: 7088-7098.
[6] Yang JJ, Nie Y, Wang F, et al. Reciprocal regulation of miR-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy[J]. Biochim Biophys Acta, 2013, 1831: 1386-1394.
[7] Yang J, Xu J, Han X, et al. Lysophosphatidic acid is associated with cardiac dysfunction and hypertrophy by suppressing autophagy via the LPA3/AKT/mTOR pathway[J].Front Physiol, 2018, 9:1315.doi:10.3389/fphys.2018.01315.
[8] Li Z, Song Y, Liu L, et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation[J]. Cell Death Differ, 2017, 24: 1205-1213.
[9] Yan HL, Wang H, Zhu XX, et al. PGC-1alphaAdeno-associated virus-mediated delivery of anti-miR-199a tough decoys attenuates cardiac hypertrophy by targeting[J]. Mol Ther Nucleic Acids, 2021, 23: 406-417.
[10] Duygu B, Poels EM, Juni R, et al. miR-199b-5p is a regulator of left ventricular remodeling following myocardial infarction[J]. Noncoding RNA Res, 2017, 2: 18-26.
[11] Zhou Y, Li KS, Liu L, et al. MicroRNA132 promotes oxidative stressinduced pyroptosis by targeting sirtuin 1 in myocardial ischaemiareperfusion injury[J].Int J Mol Med, 2020, 45:1942-1950.
[12] Man AWC, Li H, Xia N.The role of sirtuin1 in regulat-ing endothelial function, arterial remodeling and vascular aging[J].Front Physiol, 2019, 10:1173.doi:10.3389/fphys.2018.01315.
[13] Li F, Li SS, Chen H, et al. miR-320 accelerates chronic heart failure with cardiac fibrosis through activation of the IL6/STAT3 axis[J]. Aging (Albany NY), 2021, 13: 22516-22527.
[14] Jia GZ, Liang CG, Li WH, et al. miR-410-3p facilitates Angiotensin Ⅱ-induced cardiac hypertrophy by targeting Smad7[J]. Bioengineered, 2022, 13: 119-127.
[15] Shi JY, Chen C, Xu X, et al. miR-29a promotes pathological cardiac hypertrophy by targeting the PTEN/AKT/mTOR signalling pathway and suppressing autophagy[J]. Acta Physiol (Oxf), 2019, 227: 13323.doi:10.1111/apha.13323.
[16] Kura B, Kalocayova B, LeBaron TW, et al. Regulation of microRNAs by molecular hydrogen contributes to the prevention of radiation-induced damage in the rat myocardium[J]. Mol Cell Biochem, 2019, 457: 61-72.
[17] He R, Ding C, Yin P et al. miR-1a-3p mitigates isoproterenol-induced heart failure by enhancing the expression of mitochondrial ND1 and COX1.[J].Exp Cell Res, 2019, 378: 87-97.
[18] Zhao L, Li W, Zhao H.Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p.[J]. Am J Transl Res, 2020, 12: 718-730.
[19] Yuan Y, Wang J, Chen QX, et al. Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865: 1421-1427.
[20] Long YD, Wang L, Li ZQ.SP1-induced SNHG14 aggravates hypertrophic response in in vitro model of cardiac hypertrophy via up-regulation of PCDH17.[J].J Cell Mol Med, 2020, 24: 7115-7126.
[21] Salamon I, Biagini E, Kunderfranco P, et al. Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson-Fabry disease[J]. Cell Death Dis, 2021, 12: 1150.doi:10.1038/s41419-021-04438-5.
[22] Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, et al. A novel circulating microRNA for the detection of acute myocarditis[J]. N Engl J Med, 2021, 384: 2014-2027.
[23] Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study[J]. Eur Heart J, 2021, 42: 178-188.

微小RNAs在心肌肥厚中作用和分子机制的研究进展

Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	秦玉春, 邝向东, 蔡林再, 谢景臣, 陈山. 双氢青蒿素减轻慢性阻塞性肺疾病(COPD)模型大鼠肺损伤[J]. 基础医学与临床, 2023, 43(3): 427-432.
[2]	王卉, 苏宪, 张赢赢, 褚战亚, 孙朝晖, 张金玲, 张倩倩. 异鼠李素减轻糖尿病视网膜病变大鼠视网膜细胞凋亡[J]. 基础医学与临床, 2023, 43(2): 265-270.
[3]	杨孟迪, 丁雨露, 王玉洁, 何风英, 孙琳楠, 甄东户. MicroRNA在糖尿病性骨质疏松症中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 311-316.
[4]	邱立彬, 张新才, 赵倩. LncRNA DANCR靶向miR-3646减轻缺氧诱导的大鼠心肌细胞系H9c2的损伤[J]. 基础医学与临床, 2023, 43(1): 144-151.
[5]	阮锋, 李贺伟, 龚艳琳, 刘佳丽, 刘平. 过表达miR-217调控EZH2促进骨质疏松模型小鼠BM-MSCs成骨分化[J]. 基础医学与临床, 2022, 42(9): 1406-1413.
[6]	蒲超, 张珊珊, 吴青霞, 罗栩伟, 王亮, 张波. Lnc000727促进人骨髓间充质干细胞向成骨细胞分化[J]. 基础医学与临床, 2022, 42(7): 1047-1052.
[7]	张宇飞, 朱基彦, 瞿思遥, 张祝琴, 刘德培. 去泛素化酶OTUB1参与细胞铜缺乏的应答[J]. 基础医学与临床, 2022, 42(7): 1020-1025.
[8]	谢兴文, 钟建春, 李鼎鹏, 黄睿, 李宁, 郭云龙, 翟伯宇. 薯蓣皂苷防治原发性骨质疏松的研究进展[J]. 基础医学与临床, 2022, 42(6): 960-963.
[9]	陈勇, 庞红利, 许远征, 毛珊珊, 洪道先. 氯胺酮减轻大鼠脊髓缺血/再灌注损伤[J]. 基础医学与临床, 2022, 42(4): 622-627.
[10]	李蓉, 朱含月. 酮咯酸氨丁三醇抑制膝骨关节炎模型大鼠炎性反应[J]. 基础医学与临床, 2022, 42(3): 417-422.
[11]	杨芒庄, 杨旭东, 王晓龙. Circ-MALAT1靶向miR-101抑制膀胱癌细胞系SW780侵袭和迁移[J]. 基础医学与临床, 2022, 42(3): 472-478.
[12]	牛世伟, 苏韫, 龚红霞, 李婷婷, 曾元丁, 张晗, 聂蓬. 胃癌患者血清IL-1的升高和癌组织JAK2/STAT3信号通路的激活[J]. 基础医学与临床, 2022, 42(3): 401-405.
[13]	陈茜, 刘宪, 崔南, 翟阳. 敲除EZH2抑制人宫颈癌细胞系迁移和侵袭[J]. 基础医学与临床, 2022, 42(3): 395-400.
[14]	邓九红, 郑超, 王声遥, 王心怡. 醋酸泼尼松对糖尿病肾病模型大鼠肾功能、肾脏炎性反应及AMPK/SIRT1信号通路的影响[J]. 基础医学与临床, 2022, 42(2): 243-248.
[15]	景建闯, 张志军. 依托咪酯减轻LPS诱导的小鼠急性肺损伤[J]. 基础医学与临床, 2022, 42(12): 1823-1828.